Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ SIGLEC9 Monoclonal Antibody (7G4A6)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA548729
Description
SIGLEC9 Monoclonal Antibody for Western Blot, Flow, ELISA
SIGLEC9 (Sialic acid-binding Ig-like lectin 9) is a putative adhesion molecule that mediates sialic-acid dependent binding to cells. It contains two Ig-like C2 type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It preferentially binds to alpha2, 3-or alpha2, 6-linked sialic acid. The sialic acid recognition site may be mased by cis interactions with sialic acids on the same cell surface.
Specifications
SIGLEC9 | |
Monoclonal | |
1 mg/mL | |
PBS with 0.05% sodium azide | |
Q9Y336 | |
SIGLEC9 | |
Purified recombinant fragment of human CD329 (AA: extra 18-348) expressed in E. Coli. | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG1 |
ELISA, Flow Cytometry, Western Blot | |
7G4A6 | |
Unconjugated | |
SIGLEC9 | |
Cd170; CD329; CDw329; FOAP-9; LOC100062855; LOC719831; MIS; mSiglec-E; Myeloid inhibitory siglec; OBBP-LIKE; Protein FOAP-9; sialic acid binding Ig like lectin 9; sialic acid binding Ig-like lectin 5; sialic acid binding Ig-like lectin 9; sialic acid binding Ig-like lectin E; sialic acid-binding Ig-like lectin 12; Sialic acid-binding Ig-like lectin 5; sialic acid-binding Ig-like lectin 9; Sialic acid-binding Ig-like lectin E; sialic acid-binding Ig-like lectin-like 1; sialic acid-binding immunoglobulin-like lectin E; Siglec; Siglec12; siglec-12; Siglec5; Siglec-5; SIGLEC9; siglec-9; Siglece; Siglec-E; Siglecl1; siglec-L1; SIGLEC-like 1; UNQ668/PRO1302 | |
Mouse | |
Protein G | |
RUO | |
27180 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction